Philip Fisher's 1958 Scuttlebutt Method — the discipline of verifying management claims against customers, suppliers, ex-employees and trade journals — remains the most underused primary-research tool for Indian value investors in 2026. Illustrated with Titan Biotech FY25 audited disclosures.
The CFO/PAT ratio is the single fastest earnings-quality check any Indian value investor can run — and Titan Biotech FY25 audited numbers show what disciplined cash-backed profits actually look like.
Tversky & Kahneman's 1973 availability heuristic explains why Indian retail investors chase recent headlines. A detailed teaching post with an illustrative Titan Biotech FY25 case study on availability-resistant corporate behaviour.
Why serious investors should read segment notes to discover where the real business quality sits, and how Titan’s geographic split strengthens trust in the disclosure.